Contraline

Private

Charlottesville-based clinical-stage biopharma developing NES/T Gel (segesterone acetate + testosterone), a reversible male contraceptive gel. Phase 2b complete with 462 couples; Phase 3 expected 2027. Also developing the ADAM hydrogel vas deferens implant. Founded 2015.

Founders Kevin Eisenfrats

CEO Kevin Eisenfrats

Company

Founded

2015

Headquarters

Charlottesville, USA

Financials

Total Funding

$110M

Sectors

Healthtech Biotech

contraline.com

Funding History

3 rounds

Series B Jun 2, 2026

$93M

BVF Partners (Lead) RA Capital Management GV Lumira Ventures Invus

Series A Sep 1, 2021

$11M

MBX Capital (Lead)

Seed Sep 1, 2018

$7M

GV (Lead) MBX Capital Rhia Ventures Shangbay Capital Founders Fund Metaplanet Graphene Ventures Smith Ventures

Funding data is compiled from multiple independent sources including company announcements, press coverage, and regulatory filings. While we strive for accuracy, amounts and dates may reflect reported figures at time of announcement.